Bernstein raises Johnson & Johnson stock price target on solid Q3
Bernstein raised its price target for Johnson & Johnson (JNJ) to $270 from $261, citing solid Q3 results with 6.1% organic sales growth and EPS beating expectations. The stock is up 24.7% YTD but trades above its Fair Value of $243. Management raised fiscal 2026 guidance but expects flat 2027 EPS growth due to various factors. RBC lowered its target to $280 from $290, maintaining an Outperform rating.
How this was made
The 30-second read
Why it matters
Analyst target changes reflect differing views on JNJ's near‑term outlook.
Market read
The mixed analyst actions provide a nuanced view of JNJ's valuation after earnings.
What to watch
Potential impact of talc litigation charge and upcoming fiscal 2027 earnings reset.
Background
Bernstein's upgrade follows Johnson & Johnson's Q3 earnings beat and guidance lift, while RBC lowered its target.
Ticker impact
Bernstein raised its price target on Johnson & Johnson to $270, citing solid Q3 results and bullish outlook.
likely slight upward pressure as investors price in the higher target.
The price target increase is a new analyst action, but earnings were already reported, limiting impact.
Market effects
May reinforce positive sentiment in the healthcare sector.
Limited to U.S. markets where JNJ trades.
Minimal global effect beyond JNJ exposure.
Counterpoint
The target raise may be premature given lingering litigation and MedTech weakness.
Key entities
- companyJohnson & Johnson
US healthcare conglomerate reporting Q3 results.
- analyst_firmBernstein
Raised JNJ price target to $270.
- analyst_firmRBC Capital
Lowered JNJ price target to $280.
